Payment overview · 2025
General Payments
$496.13
36 reported records · 13 companies
Healthcare provider profile · identity verified
Troy D Potter, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TEXARKANA, TX · NPI 1265432645
Verified facts
What the public records show
CMS Open Payments records show Troy D Potter, MD received $496.13 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $136.19 | 27.4% | 18 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $70.61 | 14.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.61 | 12.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.21 | 9.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.32 | 6.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.13 | 5.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $24.50 | 4.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.78 | 4.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.07 | 3.4% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $14.71 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.58 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.41 | 2.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.01 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $496.13 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.19 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $112.19 | 16 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $70.61 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.61 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $49.21 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.32 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.32 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.00 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 218 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
110 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
32 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
218 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 475 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 457 | 128 |
| Losartan Potassium | Losartan Potassium | 455 | 124 |
| Meloxicam | Meloxicam | 455 | 109 |
| Omeprazole | Omeprazole | 445 | 115 |
| Potassium Chloride | Potassium Chloride | 413 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 340 | 98 |
| Metoprolol Tartrate | Metoprolol Tartrate | 310 | 85 |
| Simvastatin | Simvastatin | 305 | 79 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 274 | 70 |
| Metformin Hcl | Metformin Hcl | 260 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 68 |
| Lisinopril | Lisinopril | 249 | 68 |
| Eliquis | Apixaban | 218 | 46 |
| Furosemide | Furosemide | 212 | 63 |
| Montelukast Sodium | Montelukast Sodium | 203 | 51 |
| Methocarbamol | Methocarbamol | 196 | 67 |
| Glimepiride | Glimepiride | 192 | 44 |
| Gabapentin | Gabapentin | 182 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 37 |
| Carvedilol | Carvedilol | 148 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 40 |
| Tramadol Hcl | Tramadol Hcl | 145 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 136 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 48 |
| Clonidine Hcl | Clonidine Hcl | 116 | 24 |
| Prednisone | Prednisone | 113 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 28 |
| Synthroid | Levothyroxine Sodium | 110 | 26 |
| Celecoxib | Celecoxib | 102 | 30 |
| Allopurinol | Allopurinol | 97 | 26 |
| Eszopiclone | Eszopiclone | 95 | 20 |
| Trazodone Hcl | Trazodone Hcl | 93 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 22 |
| Alendronate Sodium | Alendronate Sodium | 86 | 18 |
| Ozempic | Semaglutide | 84 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 81 | 22 |
| Clonazepam | Clonazepam | 80 | 14 |
| Donepezil Hcl | Donepezil Hcl | 78 | 19 |
| Chlorthalidone | Chlorthalidone | 74 | 15 |
| Lorazepam | Lorazepam | 73 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 20 |
| Sertraline Hcl | Sertraline Hcl | 68 | 22 |
| Alprazolam | Alprazolam | 66 | 14 |
| Farxiga | Dapagliflozin Propanediol | 66 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 44 |
| Nifedipine Er | Nifedipine | 61 | 13 |
| Atenolol | Atenolol | 60 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 16 |
| Nabumetone | Nabumetone | 53 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | suppressed |
| Finasteride | Finasteride | 44 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 15 |
| Spironolactone | Spironolactone | 43 | 13 |
| Ezetimibe | Ezetimibe | 42 | 11 |
| Sotalol | Sotalol Hcl | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 36 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 18 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 25 |
| Estradiol | Estradiol | 31 | 12 |
| Klor-Con M20 | Potassium Chloride | 31 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 21 | 18 |
| Linzess | Linaclotide | 21 | suppressed |
| Procto-Med Hc | Hydrocortisone | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 17 |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 15 |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 13 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Levocarnitine | Levocarnitine | 14 | suppressed |
| Teriflunomide | Teriflunomide | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $496.13 · 36 records | ABBVIE INC. | AREXVY, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, GIMOTI, IBSRELA, Korlym, LEQVIO, LINZESS, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error